Literature DB >> 34896598

Six month immunogenicity of COVID-19 mRNA-BNT162b2 vaccine in actively treated cancer patients: updated results of the Vax-On study.

F Nelli1, A Fabbri2, A Onorato2, D Giannarelli3, M A Silvestri4, G Pessina5, J R Giron Berrios2, A Virtuoso2, E Marrucci2, M Schirripa2, M Mazzotta2, V Panichi4, P Cercola5, C Signorelli2, M G Chilelli2, F Primi2, E M Ruggeri2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34896598      PMCID： PMC8660134          DOI： 10.1016/j.annonc.2021.12.001

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  5 in total

1.  mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern.

Authors:  Rishi R Goel; Mark M Painter; Sokratis A Apostolidis; Divij Mathew; Wenzhao Meng; Aaron M Rosenfeld; Kendall A Lundgreen; Arnold Reynaldi; David S Khoury; Ajinkya Pattekar; Sigrid Gouma; Leticia Kuri-Cervantes; Philip Hicks; Sarah Dysinger; Amanda Hicks; Harsh Sharma; Sarah Herring; Scott Korte; Amy E Baxter; Derek A Oldridge; Josephine R Giles; Madison E Weirick; Christopher M McAllister; Moses Awofolaju; Nicole Tanenbaum; Elizabeth M Drapeau; Jeanette Dougherty; Sherea Long; Kurt D'Andrea; Jacob T Hamilton; Maura McLaughlin; Justine C Williams; Sharon Adamski; Oliva Kuthuru; Ian Frank; Michael R Betts; Laura A Vella; Alba Grifoni; Daniela Weiskopf; Alessandro Sette; Scott E Hensley; Miles P Davenport; Paul Bates; Eline T Luning Prak; Allison R Greenplate; E John Wherry
Journal:  Science       Date:  2021-12-03       Impact factor: 63.714

2.  Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study.

Authors:  F Nelli; A Fabbri; A Onorato; D Giannarelli; M A Silvestri; J R Giron Berrios; A Virtuoso; E Marrucci; C Signorelli; M G Chilelli; F Primi; M Schirripa; M Mazzotta; E M Ruggeri
Journal:  Ann Oncol       Date:  2021-09-20       Impact factor: 32.976

3.  Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection.

Authors:  Raymond A Harvey; Jeremy A Rassen; Carly A Kabelac; Wendy Turenne; Sandy Leonard; Reyna Klesh; William A Meyer; Harvey W Kaufman; Steve Anderson; Oren Cohen; Valentina I Petkov; Kathy A Cronin; Alison L Van Dyke; Douglas R Lowy; Norman E Sharpless; Lynne T Penberthy
Journal:  JAMA Intern Med       Date:  2021-05-01       Impact factor: 21.873
  5 in total
  2 in total

1.  SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition.

Authors:  Evangelos Terpos; Michalis Liontos; Oraianthi Fiste; Flora Zagouri; Alexandros Briasoulis; Aimilia D Sklirou; Christos Markellos; Efthymia Skafida; Alkistis Papatheodoridi; Angeliki Andrikopoulou; Konstantinos Koutsoukos; Maria Kaparelou; Vassiliki A Iconomidou; Ioannis P Trougakos; Meletios-Athanasios Dimopoulos
Journal:  Cancers (Basel)       Date:  2022-06-04       Impact factor: 6.575

2.  Immunogenicity of two doses of BNT162b2 and mRNA-1273 vaccines for solid cancer patients on treatment with or without a previous SARS-CoV-2 infection.

Authors:  Nicla La Verde; Agostino Riva; Maria Silvia Cona; Arianna Gabrieli; Monica Cattaneo; Cinzia Fasola; Giuseppe Lipari; Claudia De Stradis; Valentina Favorito; Benedetta Lombardi Stocchetti; Davide Chizzoniti; Alice Covizzi; Eliana Rulli; Francesca Galli; Lorenzo Ruggieri; Anna Gambaro; Sabrina Ferrario; Davide Dalu; Maciej S Tarkowski
Journal:  Int J Cancer       Date:  2022-09-02       Impact factor: 7.316
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.